Drug Profile
AAT 009
Alternative Names: AAT-009; RQ-00000009; RQ-9Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer RaQualia Pharma
- Class Antidementias; Small molecules
- Mechanism of Action Serotonin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 17 Apr 2024 AAT 009 is still in phase I trials for Alzheimer's-disease in USA (RaQualia Pharma pipeline, April 2024)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (PO)
- 04 Mar 2021 AAT 009 is available for licensing as of 04 Mar 2021. https://askat-inc.com/